Amarin Corp Plc (AMRN)

[The Irishman]

Here’s the breakdown from UHC. If they require a “step through” step edit, then they are asking for the patient to have tried one or perhaps all three. They are not clear on that. When you look at the cardiovascular risk reduction drug list, it’s most likely the case that the patient is already taking one of the three products. So, it might be a simple PA. Again, they are not clear. We should no more after May 1st. Actually, the commercial team from Amarin should already know the answer to this question. Their managed care rep certainly has been in discussions with their counterpart at UHC. In fact, the sales reps should know how to answer this question if a doctor were to ask.

Cardiovascular Risk Reduction:
atorvastatin (generic Lipitor®), rosuvastatin (generic Crestor®), simvastatin (generic Zocor®)

Hypertriglyceridemia: fenofibrate 54 mg, 145 mg, 160 mg tablets (generic Lofibra®, Triglide®, Tricor®), omega-3 ethyl esters (generic Lovaza®)